193 related articles for article (PubMed ID: 25375241)
1. A functional approach reveals a genetic and physical interaction between ribonucleotide reductase and CHK1 in mammalian cells.
Taricani L; Shanahan F; Malinao MC; Beaumont M; Parry D
PLoS One; 2014; 9(11):e111714. PubMed ID: 25375241
[TBL] [Abstract][Full Text] [Related]
2. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.
Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y
J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980
[TBL] [Abstract][Full Text] [Related]
3. The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Labroli MA; Dwyer MP; Shen R; Popovici-Muller J; Pu Q; Wyss D; McCoy M; Barrett D; Davis N; Seghezzi W; Shanahan F; Taricani L; Beaumont M; Malinao MC; Parry D; Guzi TJ
Bioorg Med Chem; 2014 Apr; 22(7):2303-10. PubMed ID: 24588962
[TBL] [Abstract][Full Text] [Related]
4. Replication stress activates DNA polymerase alpha-associated Chk1.
Taricani L; Shanahan F; Parry D
Cell Cycle; 2009 Feb; 8(3):482-9. PubMed ID: 19177015
[TBL] [Abstract][Full Text] [Related]
5. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
7. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
8. Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction.
Rieunier G; Wu X; Harris LE; Mills JV; Nandakumar A; Colling L; Seraia E; Hatch SB; Ebner DV; Folkes LK; Weyer-Czernilofsky U; Bogenrieder T; Ryan AJ; Macaulay VM
Cancer Res; 2021 Apr; 81(8):2128-2141. PubMed ID: 33509941
[TBL] [Abstract][Full Text] [Related]
9. Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition.
Shu Z; Li Z; Huang H; Chen Y; Fan J; Yu L; Wu Z; Tian L; Qi Q; Peng S; Wei C; Xie Z; Li X; Feng Q; Sheng H; Li G; Wei D; Shan C; Chen G
Oncogene; 2020 Aug; 39(35):5721-5733. PubMed ID: 32712628
[TBL] [Abstract][Full Text] [Related]
10. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
[TBL] [Abstract][Full Text] [Related]
11. ATR-CHK1-E2F3 signaling transactivates human ribonucleotide reductase small subunit M2 for DNA repair induced by the chemical carcinogen MNNG.
Gong C; Liu H; Song R; Zhong T; Lou M; Wang T; Qi H; Shen J; Zhu L; Shao J
Biochim Biophys Acta; 2016 Apr; 1859(4):612-26. PubMed ID: 26921499
[TBL] [Abstract][Full Text] [Related]
12. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
[TBL] [Abstract][Full Text] [Related]
13. A Single Conserved Residue Mediates Binding of the Ribonucleotide Reductase Catalytic Subunit RRM1 to RRM2 and Is Essential for Mouse Development.
Specks J; Lecona E; Lopez-Contreras AJ; Fernandez-Capetillo O
Mol Cell Biol; 2015 Sep; 35(17):2910-7. PubMed ID: 26077802
[TBL] [Abstract][Full Text] [Related]
14. HPV31 utilizes the ATR-Chk1 pathway to maintain elevated RRM2 levels and a replication-competent environment in differentiating Keratinocytes.
Anacker DC; Aloor HL; Shepard CN; Lenzi GM; Johnson BA; Kim B; Moody CA
Virology; 2016 Dec; 499():383-396. PubMed ID: 27764728
[TBL] [Abstract][Full Text] [Related]
15. A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair.
Fujii N; Evison BJ; Actis ML; Inoue A
Bioorg Med Chem; 2015 Nov; 23(21):6912-21. PubMed ID: 26462050
[TBL] [Abstract][Full Text] [Related]
16. Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication.
Foskolou IP; Jorgensen C; Leszczynska KB; Olcina MM; Tarhonskaya H; Haisma B; D'Angiolella V; Myers WK; Domene C; Flashman E; Hammond EM
Mol Cell; 2017 Apr; 66(2):206-220.e9. PubMed ID: 28416140
[TBL] [Abstract][Full Text] [Related]
17. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
18. Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition.
Okonska A; Bühler S; Rao V; Ronner M; Blijlevens M; van der Meulen-Muileman IH; de Menezes RX; Wipplinger M; Oehl K; Smit EF; Weder W; Stahel RA; Penengo L; van Beusechem VW; Felley-Bosco E
Mol Cancer Ther; 2020 Feb; 19(2):552-563. PubMed ID: 31619462
[TBL] [Abstract][Full Text] [Related]
19. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
[TBL] [Abstract][Full Text] [Related]
20. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
